Evidence map›Paper›PMID 42857264›Full record

ArticleLeukemia research reports2026

Substituting pegaspargase with recombinant

Lynn Savoie, Kareem Jamani, Joseph Brandwein, Peng Wang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lynn SavoieDivision of Hematology and Hematologic Malignancies, University of Calgary, Calgary, Canada.
Kareem JamaniDivision of Hematology and Hematologic Malignancies, University of Calgary, Calgary, Canada.
Joseph BrandweinDivision of Hematology, University of Alberta, Edmonton, Alberta, Canada.
Peng WangDivision of Hematology, University of Alberta, Edmonton, Alberta, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asparaginase treatment for acute lymphoblastic leukemia/lymphoblastic lymphoma is often discontinued or interrupted due to hypersensitivity reactions (HSRs) or silent inactivation, with inferior clinical outcomes. In those instances, consensus experts recommend switching to an immunogenically distinct asparaginase preparation. This case series details experiences of 4 adult patients who developed HSRs or silent inactivation while receiving modified Dana-Farber Cancer Institute (DFCI) protocols involving pegaspargase and consequently switched to crisantaspase (JZP458), a recombinant

Indexed as

Acute lymphoblastic leukemiaAntibodiesAsparaginaseHypersensitivityLymphoblastic lymphomaSilent inactivation

Identifiers

PMID42857264
PMCPMC13651810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.